Amgen Stock Forecast, Price & News

Amgen's stock was trading at $198.65 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AMGN shares have increased by 11.9% and is now trading at $222.22.
View which stocks have been most impacted by COVID-19.

28 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 1 sell rating, 12 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Amgen.

Wall Street analysts have given Amgen a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Amgen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Amgen is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Amgen.

Amgen Inc. (NASDAQ:AMGN) announced its quarterly earnings data on Monday, November, 2nd. The medical research company reported $4.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.75 by $0.62. The medical research company earned $6.42 billion during the quarter, compared to the consensus estimate of $6.38 billion. Amgen had a return on equity of 95.55% and a net margin of 29.42%.
View Amgen's earnings history.

Amgen announced a quarterly dividend on Wednesday, October 21st. Investors of record on Monday, November 16th will be paid a dividend of $1.60 per share on Tuesday, December 8th. This represents a $6.40 annualized dividend and a dividend yield of 2.88%. The ex-dividend date of this dividend is Friday, November 13th.
View Amgen's dividend history.

Amgen issued an update on its FY20 earnings guidance on Wednesday, October, 28th. The company provided EPS guidance of $15.80-16.15 for the period, compared to the Thomson Reuters consensus estimate of $15.78. The company issued revenue guidance of $25.1-25.5 billion, compared to the consensus revenue estimate of $25.39 billion.

28 Wall Street analysts have issued 12-month price targets for Amgen's stock. Their forecasts range from $185.00 to $304.00. On average, they expect Amgen's share price to reach $254.08 in the next twelve months. This suggests a possible upside of 14.3% from the stock's current price.
View analysts' price targets for Amgen.

Some companies that are related to Amgen include Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Immunomedics (IMMU), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and United Therapeutics (UTHR).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), The Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and The Home Depot (HD).

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Amgen's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.24%), State Street Corp (5.37%), Morgan Stanley (1.47%), Nuveen Asset Management LLC (0.69%), UBS Asset Management Americas Inc. (0.57%) and Charles Schwab Investment Management Inc. (0.47%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, Ronald D Sugar and Tyler Jacks.
View institutional ownership trends for Amgen.

AMGN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Los Angeles Capital Management & Equity Research Inc., Allianz Asset Management GmbH, CIBC Private Wealth Group LLC, O Shaughnessy Asset Management LLC, AQR Capital Management LLC, Coho Partners Ltd., and LSV Asset Management. Company insiders that have sold Amgen company stock in the last year include David Piacquad, David W Meline, R Sanders Williams, and Ronald D Sugar.
View insider buying and selling activity for Amgen.

AMGN stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, California Public Employees Retirement System, Morgan Stanley, DekaBank Deutsche Girozentrale, Candriam Luxembourg S.C.A., State of Tennessee Treasury Department, ProShare Advisors LLC, and Capital Wealth Planning LLC.
View insider buying and selling activity for Amgen.

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AMGN stock can currently be purchased for approximately $222.22.

Amgen has a market capitalization of $129.37 billion and generates $23.36 billion in revenue each year. The medical research company earns $7.84 billion in net income (profit) each year or $14.82 on an earnings per share basis. Amgen employs 23,400 workers across the globe.

The official website for Amgen is www.amgen.com.

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]